Rituximab Leads to Long Remissions in Patients with Chronic Immune Thrombocytopenia

Oman Medical Journal

卷:30

Khalil Al-Farsi¹  Muhanna Al-Muslahi¹  Anil Pathare¹  Murtadha Al-Khabori¹  Khalid Al-Habsi¹  Sulayma Al-Lamki¹  Salam Al-Kindi¹  Mohammed Al-Huneini¹ 

[1] Department of Hematology, Sultan Qaboos University Hospital, Muscat, Oman;

关键词: Thrombocytopenic;    Idiopathic;    Rituximab;    Blood Platelets;    Purpura;    Idiopathic;    Rituximab;   

DOI  :  10.5001/omj.2015.24

来源: DOAJ

【 摘 要 】

Objectives: To assess the response rate and duration of response in patients with chronic immune thrombocytopenia (ITP) receiving rituximab.Methods: We retrospectively analyzed 32 consecutive patients with chronic ITP who were treated in two tertiary centers in Oman. Response assessment was based on the American Society of Hematology criteria.Results: Nineteen patients (59%) had an initial response. However, six of the 19 patients lost their response leaving 13 patients with long-lasting remissions. The median age at diagnosis was 25 years (range 14–58). The median time from diagnosis to rituximab therapy was 21 months. The median follow-up after starting rituximab was 26 months. The overall cumulative response rate was 59% (complete response 44%, partial response 15%) and the median time to respond was 30 days with a response rate of 44% at four weeks. In all responders, the cumulative rate of loss of response was 32% with a median time to lose response of 54 months.Conclusions: The use of rituximab in ITP achieves high response rate and long remission duration. Our study was limited by the small sample size and further larger prospective studies are recommended.

【 授权许可】

Unknown